Hemorrhagic complications following percutaneous kidney needle biopsy were prospectively assessed in 20 children and adolescents (age 2–17 years) undergoing a total of 22 biopsies. Macroscopic hematuria was observed in 1 case and hematocrit reduction of more than 3% in 2. Gray-scale ultrasonography performed in all patients 48 h after the biopsy detected peri- and intrarenal hematomas in 2 cases. Based on these data and those from another study on children, comparison to three similar studies in adults showed a 9.3% mean incidence of macroscopic hematuria in children versus 36.2% in adults (p < 0.01), a 9.1 versus 31.3% mean incidence of hematocrit reduction of more than 3% (p < 0.05), and a mean incidence of only 10.9% in children versus 65.6% in adults of radiologically detected peri- and intrarenal hematomas (p < 0.001). We conclude that percutaneous kidney needle biopsy in children is less traumatic than in adults. Hence when relating to hemorrhagic complications of the procedure, the two populations have to be addressed separately.

Keywords:
Kidney biopsy, Ultrasound, Hematomas
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.